WaelS.SaberMDMS

PubMed

• Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
  Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko
  Journal of Clinical Oncology. 2025-03-10
• Donor telomeres and their magnitude of shortening post-allogeneic haematopoietic cell transplant impact survival for patients with early-stage leukaemia or myelodyspla...
  Shahinaz M Gadalla, Hormuzd A Katki, Tsung-Po Lai, Paul L Auer, Casey L Dagnall
  Ebiomedicine. 2025-03-08
• Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia.
  Marcos de Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Gizelle Popradi
  American Journal of Hematology. 2025-02-24

Abstracts/Posters

• Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myelodysplastic Syndromes and Acute Myeloid Leukemia
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Myeloablative Conditioning Is Preferred for Allogeneic Transplantation of Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate but Not High Disea...
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Pediatric Intensive Care Resource Utilization Following Hematopoietic Cell Transplantation in Children with Acute Leukemia
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Epigenomic Signatures in Myelodysplastic Syndrome Patients As Predictors of Donor Compatibility and Transplant Outcome
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Ver...
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Making Progress in Graft-Versus-Host Disease Prophylaxis and Microbiome Analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/MI-Imm...
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Impact of Depth of Pretransplant Clinical Response on Outcomes of Acute Myeloid Leukemia Patients in First Complete Remission (AML-CR1) Who Undergo Allogeneic Hematopo...
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients
  Wael Saber, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Lost to Follow-up Rates Are Higher in Pediatric Than Adult Survivors, but Not By Transplant Type: A Report from the Center for International Blood and Marrow Transplan... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018